H.I.G. Capital Completes Acquisition of ITH Group Limited

H.I.G. Capital, a leading global alternative investment firm managing approximately $70 billion in capital, has finalized the acquisition of ITH Group Limited, a prominent UK provider of aseptic pharmaceutical compounding services. This acquisition was carried out in collaboration with the company's founders, Adam Bloom and Karen Hamling. The financial specifics of the deal have not been disclosed.

ITH specializes in the production of customized injectable medications tailored for patients with unique medical needs, particularly those not served by existing treatment options. The company is a market leader in the compounding services sector, focusing on chemotherapy, total parenteral nutrition, and central intravenous additives, while delivering high-quality, patient-centered medications for both adults and newborns. Additionally, ITH operates a leading digital pharmacy that supplies essential, approved medications to both private and NHS patients.

With the support of H.I.G., ITH aims to continue its strong track record of organic growth and to explore new initiatives, including increasing the company's production capacity. The existing management team will remain in place, with Adam Bloom continuing as CEO and Karen Hamling as COO.

Bloom stated that welcoming H.I.G. as a key investor marks an exciting new chapter for ITH. Since its inception in 2008, the company has seen continuous growth through investments in its workforce and improvements in patient services. ITH is proud to be a leading provider of compounding services in the UK, supporting both the NHS and the private healthcare sector. The company remains committed to expanding its service offerings, deepening its expertise in providing vital, bespoke medications, and continuously evolving its pharmacy services.

John Harper, Managing Director and Head of H.I.G. Europe Lower Middle Market LBO Teams in London, expressed enthusiasm about supporting ITH's ongoing success. He emphasized the company's proven ability to reliably deliver customized medications to both NHS and private clients in a fundamentally underserved market, combined with H.I.G.'s experience in facilitating capacity expansions within its portfolio companies, sets the stage for an exciting future for ITH.

Gordon Cameron, the non-executive chairman of ITH, acknowledged the impressive enterprise that Adam and Karen have built, which serves an essential role in the UK healthcare sector. He noted that the company's commitment to high-quality customer service has earned it a market-leading reputation for reliability. Cameron looks forward to advancing the next growth phase under H.I.G.'s investment.

Founded in 2008, ITH is headquartered in London and specializes in providing aseptic compounding services to NHS and private clients, with a particular focus on chemotherapy, total parenteral nutrition, and central intravenous services. More information can be found at ithgroup.uk.

H.I.G. Capital, established in 1993, is one of the world's preeminent alternative investment firms with a diverse portfolio spanning over 400 companies globally. With a strong emphasis on middle-market investments, H.I.G. employs a flexible, operationally-driven approach to create value in its investments. The firm manages a range of funds, including equity, credit, real estate, and infrastructure funds, and has a proven track record of investing in both profitable and underperforming companies. Its current portfolio encompasses over 100 companies with a collective revenue exceeding $53 billion.